ITOS VS CYH Stock Comparison

Performance

ITOS
10/100

ITOS returned -55.33% in the last 12 months. Based on SPY's performance of 476.36%, its performance is below average giving it a score of 10 of 100.

CYH
10/100

CYH returned -15.65% in the last 12 months. Based on SPY's performance of 14.32%, its performance is below average giving it a score of 10 of 100.

Sentiment

ITOS
72/100

ITOS had a bullish sentiment score of 71.97% across Twitter and StockTwits over the last 12 months. It had an average of 2.33 posts, 2.67 comments, and 4.00 likes per day.

CYH
67/100

CYH had a bullish sentiment score of 66.84% across Twitter and StockTwits over the last 12 months. It had an average of 2.61 posts, 1.04 comments, and 0.78 likes per day.

Technicals

ITOS
14/100

ITOS receives a 14 of 100 based on 14 indicators. 1 are bullish, 11 are bearish.

CYH
43/100

CYH receives a 42 of 100 based on 14 indicators. 5 are bullish, 7 are bearish.

Earnings

ITOS
10/100

ITOS has missed earnings 5 times in the last 20 quarters.

CYH
10/100

CYH has missed earnings 5 times in the last 20 quarters.

Profit

ITOS
31/100

Out of the last 19 quarters, ITOS has had 6 profitable quarters and has increased their profits year over year on 4 of them.

CYH
59/100

Out of the last 20 quarters, CYH has had 12 profitable quarters and has increased their profits year over year on 8 of them.

Volatility

ITOS
40/100

ITOS has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.

CYH
49/100

CYH has had a lower than average amount of volatility over the last 12 months giving it a score of 49 of 100.

Analyst Price Targets

ITOS

"Analyst Price Targets" not found for ITOS

CYH
46/100

18 analysts offer 12-month price targets for CYH. Together, they have an average target of 11.88, the most optimistic target put CYH at 19 within 12-months and the most pessimistic has CYH at 6.

All score calculations are broken down here to help you make more informed investing decisions

iTeos Therapeutics, Inc. Common Stock Summary

Nasdaq / ITOS

Healthcare

Biotechnology

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

Community Health Systems, Inc. Summary

New York Stock Exchange / CYH

Healthcare

Medical - Care Facilities

Community Health Systems, Inc. owns, leases, and operates general acute care hospitals in the United States. It offers general acute care, emergency room, general and specialty surgery, critical care, internal medicine, obstetrics, diagnostic, psychiatric, and rehabilitation services, as well as skilled nursing and home care services. The company also provides outpatient services at primary care practices, urgent care centers, free-standing emergency departments, ambulatory surgery centers, imaging and diagnostic centers, retail clinics, and direct-to-consumer virtual health visits. As of December 31, 2021, it owned or leased 83 hospitals, including 81 general acute care hospitals and two stand-alone rehabilitation or psychiatric hospitals with an aggregate of 13,289 licensed beds. The company was founded in 1985 and is headquartered in Franklin, Tennessee.

Power up your portfolio